Abstract
Histone deacetylases (HDACs) remove acetyl groups from the tails of lysine residues of histone protein in nuclear chromatin and also from acetylated sites in non-histone proteins. HDACs and histone acetyltransferases (HATs) are major influences on the level of cellular protein acetylation, and an imbalance in acetylation levels, particularly under-acetylated (hypoacetylated) histone protein has been associated with precancerous or malignant states. Consequently, small molecule inhibitors of HDACs have been synthesised and some now form a newly emerging class of anti-cancer agents that can regulate transcription and inhibit proliferation of cancer cells by inducing cell cycle arrest, differentiation and/or apoptosis, among other major biological phenomena. The different mechanism(s) of action of HDAC inhibitors compared to conventional anti-neoplastic agents provides a possibility that HDAC inhibitors may be effective for refractory cancers. Accordingly, a number of programs for the development of HDAC inhibitors as anti-cancer drugs have been initiated. This review highlights recent developments in the design, synthesis and biological properties of HDAC inhibitors in the context of potential cancer therapy.
Keywords: Histone deacetylase (HDAC), HDAC isoform, histone deacetylase inhibitor, cancer therapy, hydroxamate, zinc-binding group, benzamide, cyclic peptide
Anti-Cancer Agents in Medicinal Chemistry
Title: Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer
Volume: 9 Issue: 6
Author(s): Charles M. Marson
Affiliation:
Keywords: Histone deacetylase (HDAC), HDAC isoform, histone deacetylase inhibitor, cancer therapy, hydroxamate, zinc-binding group, benzamide, cyclic peptide
Abstract: Histone deacetylases (HDACs) remove acetyl groups from the tails of lysine residues of histone protein in nuclear chromatin and also from acetylated sites in non-histone proteins. HDACs and histone acetyltransferases (HATs) are major influences on the level of cellular protein acetylation, and an imbalance in acetylation levels, particularly under-acetylated (hypoacetylated) histone protein has been associated with precancerous or malignant states. Consequently, small molecule inhibitors of HDACs have been synthesised and some now form a newly emerging class of anti-cancer agents that can regulate transcription and inhibit proliferation of cancer cells by inducing cell cycle arrest, differentiation and/or apoptosis, among other major biological phenomena. The different mechanism(s) of action of HDAC inhibitors compared to conventional anti-neoplastic agents provides a possibility that HDAC inhibitors may be effective for refractory cancers. Accordingly, a number of programs for the development of HDAC inhibitors as anti-cancer drugs have been initiated. This review highlights recent developments in the design, synthesis and biological properties of HDAC inhibitors in the context of potential cancer therapy.
Export Options
About this article
Cite this article as:
Marson M. Charles, Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (6) . https://dx.doi.org/10.2174/187152009788679976
DOI https://dx.doi.org/10.2174/187152009788679976 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies for Targeting the Multidrug Resistance-1 (MDR1)/P-gp Transporter in Human Malignancies
Current Cancer Drug Targets Pharmacophore Modeling for Antitargets
Current Topics in Medicinal Chemistry Targeting Epithelial-Mesenchymal Transition Phenotype for Gastro-Intestinal Cancer
Current Pharmaceutical Design Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy
Current Pharmaceutical Design Aqueous Extract of Argania spinosa L. Fruits Ameliorates Diabetes in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Gold Nanoparticles Conjugated with Glycopeptides for Lectin Detection and Imaging on Cell Surface
Protein & Peptide Letters c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Current Pharmaceutical Biotechnology The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy
Current Cancer Drug Targets Utility of γH2AX as a Molecular Marker of DNA Double-Strand Breaks in Nuclear Medicine: Applications to Radionuclide Therapy Employing Auger Electron-Emitting Isotopes
Current Radiopharmaceuticals Nanotechnology: A Successful Approach to Improve Oral Bioavailability of Phytochemicals
Recent Patents on Drug Delivery & Formulation Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Pharmacogenetics of Drug Transporters
Current Pharmaceutical Design Fungal Mediated Generation of Mammalian Metabolites of Fenofibrate and Enhanced Pharmacological Activity of the Main Metabolite Fenofibric Acid
Drug Metabolism Letters The Development of Pemetrexed Diacid-Loaded Gelatin-Cloisite 30B (MMT) Nanocomposite for Improved Oral Efficacy Against Cancer: Characterization, <i>In-Vitro</i> and <i>Ex-Vivo</i> Assessment
Current Drug Delivery Development of Sugar-Based Materials for Biological Devices
Current Topics in Medicinal Chemistry The ACE Insertion/Deletion Polymorphism and Risk of Cancer, a Review and Meta-Analysis of the Literature
Current Cancer Drug Targets The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Highly Efficient, Chemoselective Syntheses of 2-Methoxy-4-substituted Pyrimidines
Letters in Organic Chemistry